<DOC>
	<DOCNO>NCT01694966</DOCNO>
	<brief_summary>Evaluation histologically proven adenoma carcinoma detection rate patient undergo full colonoscopy without mucosal contrast enhancement , obtain 200 mg Methylene Blue MMX® tablet .</brief_summary>
	<brief_title>The Safety Efficacy Methylene Blue MMX® Modified Release Tablets Administered Subjects Undergoing Screening Surveillance Colonoscopy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Males female , age 50 75 . Outpatients schedule screen surveillance colonoscopy polyp colorectal cancer ) Able comprehend full nature purpose study , include possible risk side effect . Able cooperate investigator comply requirement entire study . Signed write informed consent prior inclusion study . Patients high risk colorectal cancer e.g . ulcerative colitis Previous medical history , suspect hypersensitivity , Methylene Blue and/or formulation ' ingredient . Previous medical history , suspect hypersensitivity , PEG base bowel cleanse preparation and/or bowel cleanse formulation ' ingredient . Previous medical history gastrointestinal obstruction perforation , toxic megacolon , major colonic resection , severe diverticulitis , heart failure ( Class III IV ) , serious cardiovascular disease , ulcerative colitis Crohn 's disease .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>